Navigation Links
Oncothyreon reports second quarter 2010 financial results
Date:8/5/2010

KGaA of Darmstadt, Germany, and its U.S. affiliate, EMD Serono, Inc., resumed the worldwide clinical development program for Stimuvax(R) in non-small cell lung cancer (NSCLC), including the Phase 3 START and INSPIRE trials, following a decision by the U.S. Food and Drug Administration (FDA) to partially lift the clinical hold it placed on the Investigational New Drug (IND) application for Stimuvax in March 2010. Treatment of existing patients and enrollment of new patients in START is again underway at most centers. The clinical hold for the Phase 3 STRIDE trial in advanced breast cancer was not lifted by the FDA, and in July Merck Serono decided to close this trial.

PX-866 - Phase 1 clinical trial data for PX-866, an irreversible inhibitor of PI-3 kinase, were presented at the American Society of Clinical Oncology meeting in June. The trial was an open-label, dose escalation study in patients with advanced metastatic cancer of both an intermittent and a continuous dosing schedule, including an expansion cohort at the maximum tolerated dose for each schedule.

PX-866 was well-tolerated in both arms of this trial. The most common adverse events were mild to moderate in severity, and included diarrhea, nausea, vomiting, fatigue and reversible elevation of liver enzymes. There was no significant increase in adverse events noted in patients receiving more than two cycles of treatment in either arm of the trial.

In the continuous dosing arm, 6 of 8 patients evaluable at the time of the presentation (or 75 percent) had stable disease as the best response. In the intermittent dosing arm, 7 out of 45 evaluable patients (or 16 percent) experienced stable disease. Enrollment of additional patients in the continuous dosing arm has now been completed; additional data will be presented at the 22nd EORTC-NCI-AACR sym
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Oncothyreon announces second quarter 2010 financial results conference call
2. Oncothyreon announces presentations at upcoming investor conferences in June
3. Oncothyreon to present at the Rodman & Renshaw Annual Global Investment Conference
4. Oncothyreon reports full year and fourth quarter 2009 financial results
5. Oncothyreon reports first quarter 2010 financial results
6. Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
7. Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement
8. Oncothyreons PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover
9. Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
10. Oncothyreon announces webcast of third quarter 2009 financial results conference call
11. Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... The overall research objective was to ... and use. Most researchers outsource NGS technologies; however, ... within the next 12 months. Data accuracy and ... sequencing instruments. Disease-related research is the dominant use ... to surge, with half of the respondents planning ...
(Date:9/30/2014)... 2014 Rainbow Scientific, Inc. (RSI), ... recently opened an online store to add customer ... lines developed and manufactured by Biological Industries, Inc. ... Biological Industries’ Nutristem® serum-free, xeno-free reagents for human ... cell (hESC) culture. , The online store ...
(Date:9/30/2014)... 30, 2014 Back in the 1970’s, many ... feet. per employee, which included space for circulation and file ... Jeff Howell, partner at Nidea Corporate Real Estate / ... “By the year 2000, however, 250 square feet per ... number come down to 175 to 225 square feet, and ...
(Date:9/29/2014)... the start of the military conflicts in Iraq and ... United States with traumatic brain injury caused by exposure ... improvised explosive devices, or IEDs. Symptoms of traumatic brain ... headaches and nausea, to more severe impairments in memory ... of Defense has recognized the critical importance and complexity ...
Breaking Biology Technology:Global Next-generation Sequencing Trends 2Rainbow Scientific, Inc. opens online store for state-of-the-art stem cell culture and cytogenetic reagents 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3Modeling shockwaves through the brain 2Modeling shockwaves through the brain 3Modeling shockwaves through the brain 4
... SAN DIEGO, Sept. 24 Neurocrine Biosciences,Inc. (Nasdaq: ... the UBS Global Life Sciences Conference. The live presentation,will ... Eastern Time,(ET) /5:30 a.m. Pacific Time (PT). The presentation ... Company,s website at, http://www.neurocrine.com If you are ...
... Available Only through Professionals, New Immuno-Skin Complex(TM) Targets ... to Fight the Causes of Skin Aging, EL ... his,credit including professional esthetic treatments utilizing AHA,s, and the,category ... of Medicine at UCLA, founder of Murad Inc. and ...
... Inc., a leading developer of advanced medical devices ... J. Daniel,Cole as the company,s new Chairman of ... partner with Spray Venture Partners, a venture,capital firm ... brings twenty years of medical device operational experience,having ...
Cached Biology Technology:Murad Boosts Skin Immunity With the New Murad(R) Professional Line 2OmniSonics Appoints J. Daniel Cole Chairman of the Board 2
(Date:9/30/2014)... environmental scientists and engineers, led by Clemson University ... $5.25 million grant from the U.S. Department of ... make a direct positive impact on South Carolina ... of radioactive contaminants. , "Understanding the scientific and ... environmental aspects of nuclear technologies is imperative if ...
(Date:9/30/2014)... farm runoff in Hawaii is causing tumors in endangered ... study, published Tuesday in the peer-reviewed open-access journal ... up in algae that the turtles eat, promoting the ... internal organs. , Scientists at Duke University, the University ... (NOAA) conducted the study to better understand the causes ...
(Date:9/30/2014)... news release is available in German . ... in their behavioural response to risky situations such as ... for Ornithology now found in a long-term study on ... with both metabolic rate and ambient temperature. High metabolic ... behaviour, as in these scenarios birds were more likely ...
Breaking Biology News(10 mins):Researchers get $5.25 million to advance nuclear technologies in South Carolina 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Risky metabolism 2
... MAYWOOD, Ill. -- Most people know that too much sodium ... suggests that people trying to lower their blood pressure should ... effect to sodium. Researchers found that the ratio of ... cardiovascular disease than sodium or potassium alone. "There ...
... millions of genetic mutations has revealed four new DNA "hotspots" ... researchers led by the University of Michigan and including several ... in a just-published study. Appearing Jan. 25 in ... two other previously identified DNA sites, discovered by researchers at ...
... press release is available in French . ... study conducted by Universit de Montral researchers on ... treatment plant has revealed the presence of chemotherapy ... Bezafibrate (cholesterol reducing medication), enalapril (hypertension medication), methotrexate ...
Cached Biology News:Cutting salt isn't the only way to reduce blood pressure 2Researchers identify 4 genetic hotspots associated with psoriasis 2Researchers identify 4 genetic hotspots associated with psoriasis 3Hypertension and cholesterol medications present in water released into the St. Lawrence River 2